Five-Year Subgroup Analysis of Tafasitamab plus Lenalidomide From the Phase II L-MIND Study in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

被引：0

作者：

Duell, Johannes ^{[1
]}

Abrisqueta, Pau ^{[2
]}

Dreyling, Martin ^{[3
]}

Gaidano, Gianluca ^{[4
]}

Gonzalez Barca, Eva ^{[5
]}

Jurczak, Wojciech ^{[6
]}

Maddocks, Kami J. ^{[7
]}

Menne, Tobias ^{[8
]}

Nagy, Zsolt ^{[9
]}

Tournilhac, Olivier ^{[10
]}

Bakuli, Abhishek ^{[11
]}

Amin, Aasim ^{[12
]}

Gurbanov, Konstantin ^{[13
]}

Salles, Gilles ^{[14
]}

机构：

[1] Univ Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany

[2] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Dept Hematol, Barcelona, Spain

[3] Ludwig Maximilians Univ Hosp, Munich, Germany

[4] Univ Piemonte Orientale, Div Hematol, Dept Translat Med, Novara, Italy

[5] Univ Barcelona, Inst Catala Oncol, Hosp Duran & Reynals, Dept Hematol, Barcelona, Spain

[6] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Clin Oncol, Krakow, Poland

[7] Ohio State Univ, Dept Internal Med, Arthur G James Comprehens Canc Ctr, Wexner Med Ctr, Columbus, OH USA

[8] Newcastle Upon Tyne Hosp, Freeman Hosp, Newcastle Upon Tyne, Tyne & Wear, England

[9] Semmelweis Univ, Dept Internal Med & Hematol, Budapest, Hungary

[10] CHU Clermont Ferrand, Serv Dhematol & Therapie Cellulaire, Clermont Ferrand, France

[11] MorphoSys AG, Dept Biostat, Planegg, Germany

[12] MorphoSys AG, Dept Clin Dev, Planegg, Germany

[13] MorphoSys AG, Dept Global Patient Safety, Planegg, Germany

[14] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA

来源：

关键词：

ABCL; tafasitamab; lenalidomide; diffuse large B-cell lymphoma (DLBCL); NK cell; immunotherapy; phase II;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ABCL-482

引用

页码：S436 / S437

页数：2